Need Help?

RNA Editing in breast cancer

High-throughput sequencing screens suggest that RNA editing, which consists in the substitution of adenosine with inosine by the RNA-specific adenosine deaminase (ADAR) enzyme, occurs at several thousand positions across the human genome. Recent evidences have shown that RNA-editing could promote proliferation and carcinogenesis; however, the general principles of ADAR activity on the transcriptome and how ADAR is controlled in cancers remain to be established. The main aim of this project was to investigate the phenomenon of RNA editing in breast and other cancers. The frequency of A-to-I editing was evaluated in 58 breast cancers equally distributed among the different molecular subtypes and 10 normal breast tissues. The analysis was focused on defining: the relationship between the global amount of editing and ADAR expression; the ability to predict the level of editability of specific sites; the distribution of editing in normal and tumour samples and among different breast cancer subtypes; and the clinical, pathological and genomic factors affecting editing.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001000626 Illumina HiSeq 2000 114
EGAD00001000627 Illumina HiSeq 2000 68
EGAD00001000708 454 GS FLX Titanium 69
EGAD00010000847 49
Publications Citations
Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology.
BMC Genomics 15: 2014 1008
Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.
Cell Rep 13: 2015 277-289
Using microarray-based subtyping methods for breast cancer in the era of high-throughput RNA sequencing.
Mol Oncol 12: 2018 2136-2146